Cencora Reports Q2 Earnings Beat with Raised Guidance
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 49 minutes ago
0mins
Should l Buy COR?
Source: seekingalpha
- Earnings Beat: Cencora's Q2 non-GAAP EPS of $4.75 exceeded expectations by $0.02, demonstrating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Miss: The reported revenue of $78.4 billion, a 3.9% year-over-year increase, fell short of expectations by $2.64 billion, highlighting challenges from increased market competition and demand fluctuations.
- Guidance Raised: The company raised its adjusted diluted EPS guidance for fiscal 2026 to a range of $17.65 to $17.90, surpassing the consensus estimate of $17.61, indicating management's optimistic outlook for future performance.
- Share Repurchase Plan: Cencora plans to repurchase $1 billion in shares by the end of 2026, a move that not only aims to enhance EPS but also reflects the company's confidence in its intrinsic value.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 303.660
Low
400.00
Averages
415.38
High
440.00
Current: 303.660
Low
400.00
Averages
415.38
High
440.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora Set to Announce Q2 Earnings Results
- Earnings Announcement: Cencora (COR) is set to release its Q2 2023 earnings on May 6 before market open, with consensus EPS estimated at $4.73, reflecting a 7.0% year-over-year increase, and revenue expected at $81.04 billion, also up 7.4%, indicating strong growth potential.
- Historical Performance: Over the past two years, Cencora has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, showcasing the company's robust stability and market confidence in its financial performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 2 upward revisions and 10 downward revisions, while revenue estimates experienced 8 upward revisions and 2 downward revisions, reflecting mixed market sentiment regarding the company's future performance, which could impact investor confidence.
- Strategic Acquisition: Cencora plans to acquire EyeSouth Partners' retina business for $1.1 billion, a move that not only strengthens its market position in the ophthalmology sector but also potentially provides new revenue growth opportunities in the future.
See More
Cencora Reports Q2 Earnings Beat with Raised Guidance
- Earnings Beat: Cencora's Q2 non-GAAP EPS of $4.75 exceeded expectations by $0.02, demonstrating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Miss: The reported revenue of $78.4 billion, a 3.9% year-over-year increase, fell short of expectations by $2.64 billion, highlighting challenges from increased market competition and demand fluctuations.
- Guidance Raised: The company raised its adjusted diluted EPS guidance for fiscal 2026 to a range of $17.65 to $17.90, surpassing the consensus estimate of $17.61, indicating management's optimistic outlook for future performance.
- Share Repurchase Plan: Cencora plans to repurchase $1 billion in shares by the end of 2026, a move that not only aims to enhance EPS but also reflects the company's confidence in its intrinsic value.
See More
Cencora Reports Significant Earnings Growth in Q2
- Strong Earnings Performance: Cencora's Q2 net income reached $1.641 billion, with earnings per share (EPS) of $8.40, significantly up from last year's $717.87 million and $3.68 per share, indicating a remarkable improvement in profitability.
- Robust Adjusted Earnings: Excluding items, Cencora reported adjusted earnings of $928.07 million, or $4.75 per share, reflecting solid performance in its core business and further boosting investor confidence.
- Revenue Growth Continues: The company's revenue increased by 3.8% year-over-year to $78.355 billion, up from $75.453 billion last year, demonstrating Cencora's strengthening competitive position in the market.
- Optimistic Future Guidance: Cencora's full-year EPS guidance ranges from $17.65 to $17.90, showcasing the company's confidence in future performance and the potential for continued shareholder value enhancement.
See More
Camino Minerals Appoints New Management Team to Advance Copper Project
- Management Team Strengthening: Camino Minerals has appointed Marcelo Bruna as CEO of Cuprum SpA to advance the 50/50 joint venture Puquios copper project with Nittetsu Mining, bringing over 30 years of mining experience and overseeing more than $2.5 billion in investments, which is expected to enhance project development efficiency.
- Finance Team Establishment: A new finance team has been established to support project financial planning and debt financing, with a financing agreement expected with a Japanese lender by mid-2026 to fund the construction of the Puquios copper mine, facilitating the company's transition to production.
- Strategic Consultant Engagement: Darryl Steane has been hired as a Corporate Development Consultant to support technology development and potential expansion of the Puquios copper mine, leveraging over 20 years of global mining experience from senior roles at BHP and South32, which is anticipated to enhance the company's strategic capabilities.
- Equity Incentive Plan: Camino has granted a total of 1.17 million stock options and restricted share units with an exercise price of $0.50 per share, vesting over 36 months, aimed at incentivizing management and employees to strengthen team cohesion in support of project advancement.
See More
S&P 500 Continues Record Run Fueled by AI Spending Boom
- Earnings Season Begins: Eaton is set to report earnings on Tuesday, with expectations of a roughly 200% year-over-year increase in data center orders within its Electrical Americas segment, indicating that AI buildout is driving order growth and enhancing the company's competitiveness in the data center market.
- DuPont Performance Focus: DuPont will also report on Tuesday, with its Healthcare & Water Technologies segment expected to achieve mid-single-digit organic growth, reflecting the company's strategic direction post-electronics spin-off, and investors will closely watch for commentary on changes in customer behavior.
- Arm Holdings First Earnings Call: Arm will report earnings on Wednesday, focusing on its newly launched AI central processing unit (CPU), which, although not yet on the market, is expected to drive future cloud revenue growth, with investors keen on the health of its smartphone royalty stream.
- Corning Investor Day: Corning will hold an investor day on Wednesday, expected to update its
See More
Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
See More
Cencora Set to Announce Q2 Earnings Results
- Earnings Announcement: Cencora (COR) is set to release its Q2 2023 earnings on May 6 before market open, with consensus EPS estimated at $4.73, reflecting a 7.0% year-over-year increase, and revenue expected at $81.04 billion, also up 7.4%, indicating strong growth potential.
- Historical Performance: Over the past two years, Cencora has exceeded EPS estimates 100% of the time and revenue estimates 63% of the time, showcasing the company's robust stability and market confidence in its financial performance.
- Estimate Revision Trends: In the last three months, EPS estimates have seen 2 upward revisions and 10 downward revisions, while revenue estimates experienced 8 upward revisions and 2 downward revisions, reflecting mixed market sentiment regarding the company's future performance, which could impact investor confidence.
- Strategic Acquisition: Cencora plans to acquire EyeSouth Partners' retina business for $1.1 billion, a move that not only strengthens its market position in the ophthalmology sector but also potentially provides new revenue growth opportunities in the future.
See More
Cencora Reports Q2 Earnings Beat with Raised Guidance
- Earnings Beat: Cencora's Q2 non-GAAP EPS of $4.75 exceeded expectations by $0.02, demonstrating strong profitability and boosting investor confidence in the company's financial health.
- Revenue Miss: The reported revenue of $78.4 billion, a 3.9% year-over-year increase, fell short of expectations by $2.64 billion, highlighting challenges from increased market competition and demand fluctuations.
- Guidance Raised: The company raised its adjusted diluted EPS guidance for fiscal 2026 to a range of $17.65 to $17.90, surpassing the consensus estimate of $17.61, indicating management's optimistic outlook for future performance.
- Share Repurchase Plan: Cencora plans to repurchase $1 billion in shares by the end of 2026, a move that not only aims to enhance EPS but also reflects the company's confidence in its intrinsic value.
See More
Cencora Reports Significant Earnings Growth in Q2
- Strong Earnings Performance: Cencora's Q2 net income reached $1.641 billion, with earnings per share (EPS) of $8.40, significantly up from last year's $717.87 million and $3.68 per share, indicating a remarkable improvement in profitability.
- Robust Adjusted Earnings: Excluding items, Cencora reported adjusted earnings of $928.07 million, or $4.75 per share, reflecting solid performance in its core business and further boosting investor confidence.
- Revenue Growth Continues: The company's revenue increased by 3.8% year-over-year to $78.355 billion, up from $75.453 billion last year, demonstrating Cencora's strengthening competitive position in the market.
- Optimistic Future Guidance: Cencora's full-year EPS guidance ranges from $17.65 to $17.90, showcasing the company's confidence in future performance and the potential for continued shareholder value enhancement.
See More
Camino Minerals Appoints New Management Team to Advance Copper Project
- Management Team Strengthening: Camino Minerals has appointed Marcelo Bruna as CEO of Cuprum SpA to advance the 50/50 joint venture Puquios copper project with Nittetsu Mining, bringing over 30 years of mining experience and overseeing more than $2.5 billion in investments, which is expected to enhance project development efficiency.
- Finance Team Establishment: A new finance team has been established to support project financial planning and debt financing, with a financing agreement expected with a Japanese lender by mid-2026 to fund the construction of the Puquios copper mine, facilitating the company's transition to production.
- Strategic Consultant Engagement: Darryl Steane has been hired as a Corporate Development Consultant to support technology development and potential expansion of the Puquios copper mine, leveraging over 20 years of global mining experience from senior roles at BHP and South32, which is anticipated to enhance the company's strategic capabilities.
- Equity Incentive Plan: Camino has granted a total of 1.17 million stock options and restricted share units with an exercise price of $0.50 per share, vesting over 36 months, aimed at incentivizing management and employees to strengthen team cohesion in support of project advancement.
See More
S&P 500 Continues Record Run Fueled by AI Spending Boom
- Earnings Season Begins: Eaton is set to report earnings on Tuesday, with expectations of a roughly 200% year-over-year increase in data center orders within its Electrical Americas segment, indicating that AI buildout is driving order growth and enhancing the company's competitiveness in the data center market.
- DuPont Performance Focus: DuPont will also report on Tuesday, with its Healthcare & Water Technologies segment expected to achieve mid-single-digit organic growth, reflecting the company's strategic direction post-electronics spin-off, and investors will closely watch for commentary on changes in customer behavior.
- Arm Holdings First Earnings Call: Arm will report earnings on Wednesday, focusing on its newly launched AI central processing unit (CPU), which, although not yet on the market, is expected to drive future cloud revenue growth, with investors keen on the health of its smartphone royalty stream.
- Corning Investor Day: Corning will hold an investor day on Wednesday, expected to update its
See More
Cardinal Health Raises 2026 Profit Forecast Amid Strong Specialty Drug Demand
- Profit Forecast Increase: Cardinal Health raised its 2026 adjusted profit forecast to between $10.7 and $10.8 per share, significantly up from the previous range of $10.15 to $10.35, reflecting strong confidence in the robust demand for high-priced specialty and branded drugs.
- Quarterly Earnings Beat: The company reported an adjusted profit of $3.17 per share for the third quarter, surpassing analyst expectations of $2.79 per share, indicating strong performance in the high-margin pharmaceuticals sector.
- Sales Miss Expectations: Despite reporting total sales of $60.9 billion for the third quarter, this figure fell short of the $61.7 billion analysts had anticipated, suggesting challenges in overall sales despite high demand.
- Specialty Drug Market Expansion: Cardinal Health is actively expanding its presence in the specialty drug market through acquisitions of physician practices and specialty care networks, aiming to diversify beyond traditional drug distribution in response to market dynamics.
See More
